The revenue miss and guidance cut are the dominant signals — COVID-19 vaccine revenue is structurally declining faster than expected. The oncology pipeline progress is real but years away from commercialization. Watch for the Q3 2026 BMS collaboration revenue recognition of €613M, which is critical to hitting the revised guidance range. The CEO transition adds execution risk during a pivotal pipeline period.
Price Chart
Executive Summary
BioNTech reported Q2 2026 revenues of €105.6M, down 60% YoY from €260.8M, driven by declining COVID-19 vaccine demand. The company posted an IFRS net loss of €820.8M (vs. €386.6M loss in Q2 2025) and cut full-year 2026 revenue guidance to €1.6-1.9B from €2.0-2.3B. Oncology pipeline progress was highlighted with 14 ongoing pivotal trials, but the revenue miss and guidance cut dominate the near-term outlook.
Key Facts
- Q2 2026 revenues of €105.6M, down 59.5% from €260.8M in Q2 2025
- IFRS net loss of €820.8M in Q2 2026, more than doubling from €386.6M loss in Q2 2025
- Full-year 2026 revenue guidance cut to €1.6-1.9B from prior €2.0-2.3B
- Adjusted R&D expenses guidance lowered to €2.0-2.3B from €2.2-2.5B
- Cash position remains strong at €16.6B as of June 30, 2026
- CEO transition: Guido Oelkers appointed, to take office by February 1, 2027
- 14 ongoing pivotal oncology trials; 6 pivotal trials initiated in H1 2026
- XFG variant-adapted COVID-19 vaccine approved by European Commission in July 2026
- Share repurchase program of up to $1.0B underway; $151.6M in ADSs repurchased in Q2
Financial Impact
Revenue decline of ~€155M YoY in Q2; full-year revenue guidance cut by €400M at midpoint; net loss widened by ~€434M YoY in Q2
Risk Factors
- COVID-19 vaccine demand continues to decline faster than anticipated
- Oncology pipeline may not generate revenue for several years, creating a revenue gap
- CEO transition could slow strategic execution
- R&D spending remains high at ~€2B+ annually, pressuring cash burn
- Milestone revenue from out-licensed program delayed beyond 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000054 |
| Document: a992bntx2q2026presentati.htm | 0001776985-26-000054 |
| Document: form6-kq22026earningsprear.htm | 0001776985-26-000054 |
| Document: 0001776985-26-000054-index-headers.html | 0001776985-26-000054 |
| Document: 0001776985-26-000054-index.html | 0001776985-26-000054 |
| Document: 0001776985-26-000054.txt | 0001776985-26-000054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access